Cerebrolysin for vascular dementia

Cochrane Database of Systematic Reviews

Volumn 2013, Issue 1, 2013, Pages

  Chen, Ning ^a   Yang, Mi ^a   Guo, Jian ^a   Zhou, Muke ^a   Zhu, Cairong ^b   He, Li ^a  

^a SICHUAN UNIVERSITY   (China)

^b SICHUAN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CEREBROLYSIN; PLACEBO; AMINO ACID; NOOTROPIC AGENT;

ALL CAUSE MORTALITY; ALZHEIMER DISEASE ASSESSMENT SCALE COGNITIVE SUBPART; ASTHENIA; CAREGIVER BURDEN; CLINICAL GLOBAL IMPRESSION SCALE; CLINICIAN INTERVIEW BASED IMPRESSION OF CHANGE PLUS CAREGIVER INPUT; CLINICIAN INTERVIEW BASED IMPRESSION OF SEVERITY; CLOCK DRAWING TEST; COGNITION; DAILY LIFE ACTIVITY; DEMENTIA ASSESSMENT; DIZZINESS; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; HASEGAWA DEMENTIA SCALE; HEADACHE; HUMAN; HYPERTENSION; HYPOTENSION; LUNG TUMOR; META ANALYSIS (TOPIC); MINI MENTAL STATE EXAMINATION; MULTIINFARCT DEMENTIA; NUREMBERG ACTIVITIES INVENTORY; PRIORITY JOURNAL; PYELONEPHRITIS; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECTOSIGMOID CANCER; REVIEW; SANDOZ CLINICAL ASSESSMENT GERIATRIC; SIGMOID CANCER; SYSTEMATIC REVIEW; TRAIL MAKING TEST; TREATMENT DURATION; TREATMENT WITHDRAWAL; WECHSLER INTELLIGENCE SCALE FOR ADULT; DRUG EFFECT; META ANALYSIS;

AMINO ACIDS; COGNITION; DEMENTIA, VASCULAR; HUMANS; NOOTROPIC AGENTS; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

MLCS; MLOWN;

EID: 84874807088     PISSN: None     EISSN: 1469493X     Source Type: Journal    
DOI: 10.1002/14651858.CD008900.pub2     Document Type: Review

References (87)

1. Guekht A, Doppler E, Moessler H, Gusev E. Cerebrolysin improves clinical outcome in moderate to moderately severe vascular dementia: results from a randomized, double-blind, placebo-controlled, multicenter trial. European Journal of Neurology. 2009; Vol. 16 (Suppl. 3):391.
2. Guekht AB, Moessler H, Novak PH, Gusev EI. Cerebrolysin in vascular dementia: improvement of clinical outcome in a randomized, double-blind, placebo-controlled multicenter trial. Journal of Stroke and Cerebrovascular Diseases 2011;20(4):310-8.
3. Novak P, NCT00947531. A clinical trial to evaluate the safety and efficacy of 20 ml Cerebrolysin in patients with Vascular Dementia (VascDem). http://clinicaltrials.gov/ct2/show/study/NCT00947531. Clinicaltrials.gov, 2009.
4. Liang SY, Li ZJ, Yan HJ, Pei XM. The efficacy of Cerebrolysin in multi-infarct dementia [Chinese Source]. Heilongjiang Medicine and Pharmacy 2001;24(5):75.
5. Muresanu DF, Alvarez XA, Moessler H, Buia M, Stan A, Pintea D, et al.A pilot study to evaluate the effects of Cerebrolysin on cognition and qEEG in vascular dementia: cognitive improvement correlates with qEEG acceleration. Journal of the Neurological Sciences 2008;267(1-2):112-9.
6. Muresanu DF, Alvarez XA, Moessler H, Novak PH, Stan A, Buzoianu A, et al.Persistence of the effects of Cerebrolysin on cognition and qEEG slowing in vascular dementia patients: results of a 3-month extension study. Journal of the Neurological Sciences 2010;299(1-2):179-83.
7. Vereschagin NV, Nekrasova YM, Lebedeva NV, Suslina ZA, Solovyev OI, Piradov MA, et al.Mild forms of multi-infarct dementia - effectiveness of Cerebrolysin. Sovetskaya Meditsina 1991;11:6-8.
8. Xiao S, Yan H, Yao P. The efficacy of Cerebrolysin in patients with vascular dementia: Results of a Chinese multicentre, randomised, double-blind, placebo-controlled trial. Hong Kong Journal of Psychiatry 1999;9(2):13-9.
9. Xiao S, Yan H, Yao PF, Wang lN, Tang HC, Jia JJ, et al.A multi-center, double blind, placebo-controlled trial of the efficacy of Cerebrolysin in treatment of vascular dementia. Journal of Clinical Psychological Medicine 1999;9(1):1-3.
10. Zhang LJ, Pan XH, Wang YH, Sheng HT. Cerebrolysin improves the intelligence of vascular dementia patients in clinic [Chinese Source]. Chinese Journal of Clinical Rehabilitation 2003;7(28):3850-1.
11. Cao G, Ma Y. Application of Cerebrolysin in ischaemic cerebrovascular disease [Chinese Source]. Clinical Focus 2000;21(15):986-7.
12. Chen H. Efficacy of Cerebrolysin for vascular dementia [Chinese Source]. Chinese Journal of Practical Medicine 2006;9(5):1019.
13. Dai Y. Efficacy of Cerebrolysin in 41 patients with vascular dementia [Chinese Source]. Chinese and Foreign Medical Research 2011;15:44-5.
14. Damulin IV, Koberskaya NN, Mkhitaryan ÉA. Effects of Cerebrolysin on moderate cognitive impairments in cerebral vascular insufficiency (a clinical-electrophysiological study). Neuroscience and Behavioral Physiology 2008;38(6):639-45.
15. Jia YP, Chen TW, Li YX. Application of Cerebrolysin in 30 patients of post stroke dementia [Chinese Source]. New Drugs and Clinical Remedies 1991;10(3):129-30.
16. Li ZL, Huang W. Application of Cerebrolysin in 20 patients with vascular dementia [Chinese Source]. Anhui Medicine 1996;5(17):41-2.
17. Meng L, Zhang YJ, Zhou YM. The efficacy of Cerebrolysin for 62 old patients with vascular dementia [Chinese Source]. Journal of Mudanjiang Medical College 2001;22(1):25-6.
18. Pan AH. Efficacy of Cerebrolysin in 20 patients with vascular dementia [Chinese Source]. Herald of Medicine 1999;3(18):147.
19. Suvorova I, Shprakh V. Neuroprotective therapy in basic treatment of vascular dementia. European Neuropsychopharmacology 2010;20:S561.
20. Tapu M, Bicu D, Tapu F, Stovicek O. The efficacy of cerebrolysin in vascular dementia. Journal of the Neurological Sciences 2009;283:286.
21. Vereschagin NV, Suslina ZA, Timerbaeva SL, Kashina EM, Gnezditsky VV, Maksimova MY, et al.Treatment and prevention of cognitive dysfunction in patients with arterial hypertension and atherosclerosis: results of randomised double blind placebo-controlled study of cerebrolysin. Terapevticheskii Arkhiv 2001;73:22-7.
22. Wang XM, Sun JT, Chen HF, Han XL, He YB. Comparative study of cytidine diphosphate choline and cerebrolysin for cerebrovascular disease and vascular dementia [Chinese Source]. New Drugs and Clinical Remedies 1996;15(4):244-5.
23. Wang Y. Efficacy of cerebrolysin in patients with multi-infarct dementia [Chinese Source]. Proceeding of Clinical Medicine 2003;12(5):362-3.
24. Xian MJ, Jiang XD, Yang Z, Li CM, Yuan L, Fang L, et al.Effect of galanthamine on memory and quality of life in patients with vascular dementia [Chinese Source]. Chinese Journal of Clinical Rehabilitation 2004;8(16):3022-3.
25. Zheng YF, Xie JM, Li WD. Efficacy of cerebrolysin for vascular dementia [Chinese Source]. Heilongjiang Medicine and Pharmacy 1999;22(3):103.
26. Aggarwal NT, Decarli C. Vascular dementia: emerging trends. Seminars in Neurology 2007;27(1):66-77.
27. Akai F, Hiruma S. Neurotrophic factor-like effect of FPF1070 on septal cholinergic neurons after transections of fimbria-fornix in the rat brain. Histology and Histopathology 1992;7(2):213-21.
28. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 3rd Edition. Washington, DC: American Psychiatric Press, 1980.
29. American Psychiatric Association. Diagnostic and statistical manual of mental disorders, 3rd edition, revised. Washington, DC: American Psychiatric Press, 1987.
30. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th Edition. Washington, DC: American Psychiatric Press, 1994.
31. Benisty S, Hernandez K, Viswanathan A. Diagnostic criteria of vascular dementia in CADASIL. Stroke 2008;39:838-44.
32. Chui HC, Victoroff JI, Margolin D. Criteria for the diagnosis of ischemic vascular dementia proposed by the state of California Alzheimer's disease diagnostic and treatment centers. Neurology 1992;42:473-80.
33. Deeks JJ, Higgins JPT, Altman DG (editors). Chapter 9: Analysing data and undertaking meta-analyses. In: Higgins JPT, Green S editor(s). Cochrane Handbook for Systematic Reviews of Intervention Version 5.1.0 (updated March 2011). Chichester: John Wiley & Sons, 2011. [: Available from www.cochrane-handbook.org.]
34. Dong MJ, Peng B, Lin XT. The prevalence of dementia in the People's Republic of China: a systematic analysis of 1980-2004 studies. Age and Ageing 2007;36:619-24.
35. Feigin V, Ratnasabapathy Y, Anderson C. Does blood pressure lowering treatment prevent dementia or cognitive decline in patients with cardiovascular and cerebrovascular disease?. Journal of the Neurological Sciences 2005;229-30:151-5.
36. Folstein MF, Folstein SE, McHugh PR. "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. Journal of Psychiatric Research 1975;12:189-98.
37. Fragoso YD, Dantas DC. Cerebrolysin for Alzheimer's disease (Protocol). Cochrane Database of Systematic Reviews 2009, Issue 3. [DOI: 10.1002/14651858.CD003801]
38. Hachinski VC, Iliff LD, Zilhka E, Du Boulay GH, McAllister VL, Marshall J, et al.Cerebral blood flow in dementia. Archives of Neurology 1975;9:632-7.
39. Hao Z, Liu M, Liu Z. Huperzine A for vascular dementia. Cochrane Database of Systematic Reviews 2009, Issue 2. [DOI: 10.1002/14651858.CD007365.pub2]
40. Hartbauer M, Hutter-Paier B, Windisch M. Effects of Cerebrolysin on the outgrowth and protection of processes of cultured brain neurons. Journal of Neural Transmission 2001;108:581-92.
41. Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Statistics in Medicine 2002;21(11):1539-58.
42. Higgins JP, Thompson SG, Deeks JJ. Measuring inconsistency in meta-analyses. BMJ 2003;327(7414):557-60.
43. Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
44. Higgins JPT, Altman DG, Sterne JAC (editors). Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green (editors). Cochrane Handbook for Systematic Reviews of Intervention Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
45. Higgins JPT, Deeks JJ (editors). Chapter 7: Selecting studies and collecting data. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
46. Higgins JPT, Deeks JJ, Altman DG (editors). Chapter 16: Special topics in statistics. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
47. Hong Z, Zhu GX, Chen HB, Chen SD, Yang QD, Zeng JS, et al.The clinical efficacy of Cerebrolysin in the treatment of acute ischemic stroke [Chinese Source]. Chinese Journal of Geriatric Heart Brain and Vessel Diseases 2005;7:331-3.
48. International Conference on Harmonisation Expert Working Group. International Conference on Harmonisation of technical requirements for registration of Pharmaceuticals for human use adopts Consolidated Guideline on Good Clinical Practice in the Conduct of Clinical Trials on Medicinal Products for Human Use. International Digest of Health Legislation. 1997; Vol. 48:231-4.
49. Kavirajan H, Schneider LS. Efficacy and adverse effects of cholinesterase inhibitors and memantine in vascular dementia: a meta-analysis of randomised controlled trials. The Lancet Neurology 2007;6:782-92.
50. Korczyn AD, Vakhapova V, Grinberg LT. Vascular dementia. Journal of the Neurological Sciences 2012;322(1-2):2-10.
51. Ladurner G, Kalvach P, Moessler H. Cerebrolysin Study Group. Neuroprotective treatment with cerebrolysin in patients with acute stroke: a randomised controlled trial. Journal of Neural Transmission 2005;112(3):415-28.
52. Masliah E, Armasolo F, Veinbergs I, Mallory M, Samuel W. Cerebrolysin ameliorates performance deficits, and neuronal damage in apolipoprotein E-deficient mice. Pharmacology Biochemistry and Behaviour 1999;62:239-45.
53. McGuinness B, Todd S, Passmore P. Blood pressure lowering in patients without prior cerebrovascular disease for prevention of cognitive impairment and dementia. Cochrane Database of Systematic Reviews 2009, Issue 4. [DOI: 10.1002/14651858.CD004034.pub3]
54. Mohs RC, Knopman D, Petersen RC, Ferris SH, Ernesto C, Grundman M, et al.Development of cognitive instruments for use in clinical trials of antidementia drugs: additions to the Alzheimer's Disease Assessment Scale that broaden its scope. The Alzheimer's Disease Cooperative Study. Alzheimer Disease & Associated Disorders 1997;11(Suppl 2):S13-21.
55. Moorhouse P, Rockwood K. Vascular cognitive impairment: current concepts and clinical developments. The Lancet Neurology 2008;7:246-55.
56. Muresanu DF, Alvarez XA, Moessler H, Buia M, Stan A, Pintea D, et al.A pilot study to evaluate the effects of Cerebrolysin on cognition and qEEG in vascular dementia: cognitive improvement correlates with qEEG acceleration. Journal of the Neurological Sciences 2008;267(1-2):112-9.
57. Muresanu DF, Alvarez XA, Moessler H, Novak PH, Stan A, Buzoianu A, et al.Persistence of the effects of Cerebrolysin on cognition and qEEG slowing in vascular dementia patients: results of a 3-month extension study. Journal of the Neurological Sciences 2010;299(1-2):179-83.
58. Nasreddine ZS, Phillips NA, Bédirian V, Charbonneau S, Whitehead V, Collin I, et al. The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment. Journal of the American Geriatric Society 2005;53(4):695-9.
59. Neuropathology Group. Medical Research Council Cognitive Function and Aging Study. MRC/CFAS: pathological correlates of late-onset dementia in a multicentre, community-based population in England and Wales. Lancet 2001;357:169-75.
60. O'Brien JT, Erkinjuntti T, Reisberg B. Vascular cognitive impairment. The Lancet Neurology 2003;2(2):89-98.
61. O'Brien JT. Vascular cognitive impairment. American Journal of Geriatric Psychiatry 2006;14:724-33.
62. Pantoni L, Inzitari D. Hachinski's ischemic score and the diagnosis of vascular dementia: A review. Italian Journal of Neurological Sciences 1993;14:539-46.
63. Plosker GL, Gauthier S. Cerebrolysin: a review of its use in dementia. Drugs and Aging 2009;26(11):893-915.
64. Plosker GL, Gauthier S. Spotlight on cerebrolysin in dementia. CNS Drugs 2010;24(3):263-6.
65. Rainer M, Brunnbauer M, Dunky A, Ender F, Goldsteiner H, Holl O, et al. Therapeutic results with Cerebrolysin in the treatment of dementia. Wiener Medizinische Wochenschrift 1997;147(18):426-31.
66. Renna M, Handy J, Shah A. Low baseline Bispectral Index of the electroencephalogram in patients with dementia. Anesthesia and Analgesia 2003;96(5):1380-5.
67. TM in a transgenic model of Alzheimer's disease are associated with improved behavioral performance. Journal of Neural Transmission 2003;110:1313-27.
68. Rockenstein E, Adame A, Mante M. Amelioration of the cerebrovascular amyloidosis in a transgenic model of Alzheimer's disease with the neurotrophic compound cerebrolysin. Journal of Neural Transmission 2005;112(2):269-82.
69. Rockenstein E, Torrance M, Mante M, Adame A, Paulino A, Rose JB, et al.Cerebrolysin decreases amyloid-beta production by regulating amyloid protein precursor maturation in a transgenic model of Alzheimer's disease. Journal of Neuroscience Research 2006;83:1252-61.
70. Román GC, Tatemichi TK, Erkinjuntti T, Cummings JL, Masdeu JC, Garcia JH, et al.Vascular dementia. Diagnostic criteria for research studies: Report of the NINDS-AIREN International Workshop. Neurology 1993;43:250-60.
71. Román GC. Vascular dementia revisited: diagnosis, pathogenesis, treatment, and prevention. Medical Clinics of North America 2002;86(3):477-99.
72. Satou T, Imano M, Akai F. Morphological observation of effects of Cerebrolysin on cultured neural cells. Advances in the Biosciences 1993;87:195-6.
73. Srikanth VK, Quinn SJ, Donnan GA. Long-term cognitive transitions, rates of cognitive change, and predictors of incident dementia in a population-based first-ever stroke cohort. Stroke 2006;37(10):2479-83.
74. Sterne JAC, Egger M, Moher D (editors). Chapter 10: Addressing reporting biases. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Intervention. Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
75. Tatebayashi Y, Lee MH, Li L, Iqbal K, Grundke-lqbal I. The dentate gyrus neurogenesis: a therapeutic target for Alzheimer's disease. Acta Neuropathologica 2003;105(3):225-32.
76. Veinbergs I, Mante M, Mallory M. Neurotrophic effects of Cerebrolysin in animal models of excitotoxicity. Journal of Neural Transmission Supplement 2000;59:273-80.
77. Viswanathan A, Rocca WA, Tzourio C. Vascular risk factors and dementia: how to move forward?. Neurology 2009;72(4):368-74.
78. Wei ZH, He QB, Wang H, Su BH, Chen HZ. Meta-analysis: the efficacy of nootropic agent Cerebrolysin in the treatment of Alzheimer's disease. Journal of Neural Transmission 2007;114(5):629-34.
79. World Health Organization. The 10th revision of the International Classification of Disease and relative health problems (ICD-10). Geneva: World Health Organization, 1992.
80. Windisch M, Gschanes A, Hutter-Paier B. Neurotrophic activities and therapeutic experience with a brain derived peptide preparation. Journal of Neural Transmission Supplement 1998;53:289-98.
81. Wu TX, Li QP, Yuan ZY. Yizhi capsule for vascular dementia. Cochrane Database of Systematic Reviews 2007, Issue 2. [DOI: 10.1002/14651858.CD005382.pub2]
82. Zhang YD, Xu Y, Nie HW, Lei T, Wu Y, Zhang L, et al.Prevalence of dementia and major dementia subtypes in the Chinese populations: A meta-analysis of dementia prevalence surveys, 1980-2010. Journal of Clinical Neuroscience 2012;19(10):1333-7.
83. Ziganshina LE, Abakumova T, Kuchaeva A. Cerebrolysin for acute ischemic stroke. Cochrane Database of Systematic Reviews 2010, Issue 4. [DOI: 10.1002/14651858.CD007026]
84. Álvarez XA, Sampedro C, Pérez P, Laredo M, Couceiro V, Hernández Á, et al.Positive effects of Cerebrolysin on electroencephalogram slowing, cognition and clinical outcome in patients with postacute traumatic brain injury: an exploratory study. International Clinical Psychopharmacology 2003;18(5):271-8.
85. Álvarez XA, Cacabelos R, Laredo M. A 24-week, double-blind, placebo-controlled study of three dosages of Cerebrolysin in patients with mild to moderate Alzheimer's disease. European Journal of Neurology 2006;13(1):43-54.
86. Álvarez XA, Cacabelos R, Sampedro C, Aleixandre M, Linares C, Granizo E, et al.Efficacy and safety of Cerebrolysin in moderate to moderately severe Alzheimer's disease: results of a randomized, double-blind, controlled trial investigating three dosages of Cerebrolysin. European Journal of Neurology 2011;18(1):59-68.
87. Álvarez XA, Fuentes P. Cerebrolysin in Alzheimer's disease. Drugs Today (Barc) 2011;47(7):487-513.